Advantages of the Vaxart Vaccine Platform
- Oral delivery is strongly preferred by care providers and patients.
- New vaccines can be created very quickly to protect against new circulating avian flu strains, other emerging pathogens, or biodefense threats.
- Vaxart uses efficient and standardized manufacturing methods, with essentially the same process for every Vaxart vaccine.
- Vaxart vaccines retain potency for more than a month at room temperature, potentially allowing final distribution without refrigeration or the need for administration by trained medical staff.
- Vaxart vaccines generate antigen-specific killer T-cell and IgA antibody responses, as well as IgG antibody responses.
- Oral vaccination with live adenovirus (to prevent respiratory adenovirus infection) has an excellent safety record in millions of subjects.
News
October 2008: Vaxart reports demonstration of oral vaccine efficacy against lethal avian flu challenge in ferret and mouse models, at Modern Mucosal Vaccines Adjuvants & Microbicides conference in Portugal. Read more...
June 2008: Vaxart presents at BIO International Conference in San Diego.
March 2008: Robert Fildes, former President of Biogen and CEO of Cetus, joins Vaxart Board as Chairman. Read more...
January 2008: Vaxart profiled in Startup (Windhover publications).
November 2007: Vaxart (fka West Coast Biologicals) Completes Series A Financing. Read more...
November 2007: NAIAD division of NIH awards $600,000 SBIR grant to Vaxart to develop oral vaccine platform.
April 2006: West Coast Biologicals is a finalist in the 2006 Global Life Sciences Innovation Accelerator Competition at UCSF.